

Our facility
A core unit within the Translational Neuroscience Facility in the School of Biomedical Sciences, UNSW Sydney, directed towards treatment of neurological disorders. Collaborating teams focus on therapeutic applications linked to hearing loss, leukodystrophies (genetic disorders that affect the CNS white matter), neuroprotection in stroke and traumatic brain injury, neuro-immunological basis of neuropathic pain, neural regeneration, CNS neural plasticity underlying memory & addiction; neural coding; industry collaborations in small molecule and DNA / RNA therapeutics supporting translation through novel therapeutic approaches for reducing brain injury from stroke, brain trauma & epilepsy. Targeting gene expression in the nervous system; adeno-associated virus viral vector core; proprietary non-viral focal gene electrotransfer (BaDGE®); multiphoton physiological imaging; electrophysiology; transgenic mouse models of CNS pathophysiologies.
Our Research
The Sensori-Motor Physiology & Therapeutics (SMPT) research program spans neuro-protection, neuro-repair, medical bionics, and DNA therapeutics targeting the nervous system and muscle function. A principal area of research concerns the molecular and cellular basis of hearing loss focusing on cell signalling that contributes to sensory hair cell injury and auditory synaptopathy due to noise and aging.
An applied arm is the development of BaDGE® (bionic array – directed gene electrotransfer) which in a first-in-human clinical trial is enabling targeted delivery of DNA encoding neurotrophin genes into the cochlea to stimulate regeneration of the auditory nerve fibres in cochlear implant recipients. BaDGE® is a platform technology for precise delivery of naked DNA throughout the body, including brain and muscle.
The SMPT program extends to neuroprotection studies directed at reduction of excitotoxicity driving synaptopathy and brain injury, and neuromodulation in targeted brain regions with application across stroke, TBI, epilepsy & Parkinson’s Disease.
Highlighted publications
- Jeremy L. Pinyon, Georg von Jonquieres, Stephen L. Mow, Amr Al Abed, Keng-Yin Lai, Mathumathi Manoharan, Edward N. Crawford, Stanley H. Xue, Sarah Smith-Moore, Lisa J. Caproni, Sarah Milsom, Matthias Klugmann, Nigel H. Lovell, Gary D. Housley. ‘Vector-Free Deep Tissue Targeting of DNA/RNA Therapeutics via Single Capacitive Discharge Conductivity-Clamped Gene Electrotransfer’, Advanced Science 3/2025 (https://doi.org/10.1002/advs.202406545, opens in a new window)
- Gene Electrotransfer via Conductivity-Clamped Elec...
- The Team
- Adjunct team members
A vibrant group of research scientists with expertise in Auditory Neuroscience, Cell and Molecular Biology, Gene therapy, Neuroimmunology, Neurophysiology, Electrophysiology and CNS disorders.
Capabilities
- Neurophysiology
- Optogenetics
- Intravital multiphoton imaging
- Genetically-encoded Ca2+ reporter brain injury readout
- Brain slice patch-clamp ion channel studies
- Evoked field potential electrophysiology (auditory & visual)
- AAV viral vector gene core
- Mouse transgenics & behavioural phenotyping
- BaDGE® platform for gene electrotransfer therapeutics
Impact and Applications
Gary Housley - Group Leader
Gary Housley, PhD, holds the Chair of Physiology and is director of the Translational Neuroscience Facility, School of Medical Sciences, UNSW Australia. His research program is broadly within molecular, cellular and systems physiology in the nervous system, particularly around neuroprotection in the CNS and auditory system. He has contributed prominently to understanding how hearing adapts to noise and ageing. Study of neural development and synaptic plasticity in the auditory system informs on gene-targets for neural repair. This research has an applied arm with respect to bionics such as the cochlear implant which has led to development of an innovative gene therapy platform for auditory nerve regeneration which is currently in a first-in-human clinical trial (www.cingt.info). Hearing loss is the most prominent sensory disability in our society. Stroke is the third highest killer and the most disabling for survivors. Leader for development of UNSW Sydney patented technology for delivery of DNA and RNA therapeutics. BaDGE® - Bionic array Directed Gene Electrotransfer.
Within the brain, Housley's research group are investigating neural plasticity associated with driven input ( e.g. via the cochlear implant) and mechanisms for protection and repair of the nervous system (focusing of the role of calcium signalling in excitotoxicity, associated with ischaemic brain injury, stroke, epilepsy and traumatic brain injury. The research is supported by national and international collaborations and funding.
Collaborators
Prof. Allen Ryan (Univ. California, San Diego, USA); Prof. Peter Thorne, Dr. Srdjan Vlajkovic (University of Auckland, New Zealand), Prof. Jean-Pierre Julien (Laval University, Quebec, CAD), Prof. Lutz Birnbaumer (Buenos Aires, Argentina) Prof. Shin-ichi Usami (Shinshu Univ., Japan); Prof. Junichi Nabekura (National Institute of Physiological Sciences, Okazaki, Japan)
BaDGE® - CINGT collaborators: Scientia Prof. Nigel Lovell (UNSW); A/Prof. Matthias Klugmann (UNSW); Prof. Daniel Scherman and Dr. Corinne Marie (School of Pharmacy, Descartes, Paris), Prof. Anne Schielder (Otolarynology, UCL, London); Ya Lang Enke (Cochlear), Paul Carter (Cochlear), Jim Patrick (Cochlear), Saji Maruthurkkara (Cochlear), Lisa Nelson (UNSW), Catherine Birman (Sydney Cochlear Implant Centre), Colleen Psarros (Sydney Cochlear Implant Centre), Wai Kong Lai (Sydney Cochlear Implant Centre), Halit Sanli (Sydney Cochlear Implant Centre), Catherine McMohan (Macquarie University), David McAlpine (Macquarie University), Jaime Undurraga (Macquarie University), Fiona Odams (Macquarie University), Phillip Nakad (Macquarie University), Robert Shepherd (Bionics Institute), James Fallon (Bionics Institute), Andrew Wise (Bionics Institute).

Industry partners
Cochlear Ltd (Dr. Jim Patrick , Dr. Martin Svehla)
Roche Palo Alto (Dr. Deborah Cockayne)
Nyrada Inc.